Price
$36.34-1.28%Social Signal Score
Analyst Ratings
15 analystsRevenue
$1.44M-91.54%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Matthew Gline
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 721
- Beta
- 1.12
- Country
- GB
- Piotroski score
- 0 / 9 (Weak)
- Altman Z-score
- 40.85
Financials
Revenue
$1.44M-91.5%Net Income
$-189.83MEBITDA
$-288.27MFree Cash Flow
$-263.81MEPS (diluted)
$-0.26Shares Outstanding (diluted)
720.78M+1.0%Operating Expenses
$367.54MCash & Debt
$3.84BReturn of Capital
$206.73MRevenue by Segment (annual)
$8.26MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $8.26M | $-299.77M | $-0.43 |
| 2024 | $29.05M | $-171.98M | $-0.24 |
| 2023 | $32.71M | $4.35B | $5.55 |
| 2022 | $31.53M | $-1.01B | $-1.42 |
| 2021 | $55.29M | $-845.26M | $-1.26 |
| 2020 | $23.80M | $-809.23M | $-1.18 |
| 2019 | $67.69M | $1.20B | $1.75 |
Valuation
ROIVhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
50-28.57%Social Signal Score
Mentions (19)
- Newsmarketbeat.com·8d ago·Neutral
Roivant Sciences Targets LISRAYA Launch, Key Pipeline Readouts in Next 12 Months Roivant Sciences NASDAQ: ROIV CEO Matthew Gline outlined the company's priorities for the next 12 months, including the launch of LISRAYA, upcoming clinical data for brepocitinib and Immunovant's IMVT-1402, and expansion of its pulmonary hypertension program.
View source ↗ - Newsseekingalpha.com·23d ago·Neutral
Roivant Sciences: Diverse Exposure To Biotech Niches Through Vants LISRAYA's recent approval gives ROIV a nice commercial foundation, while additional indications could turn brepocitinib into a broader immunology franchise. ROIV's pulmonary asset with mosliciguat is also promising. This candidate may be helpful for vascular resistance and walking distance improvements. I believe mosliciguat could over time become a valuable pulmonary franchise, but we still need to see how its subsequent Phase 3…
View source ↗ - Newsseekingalpha.com·25d ago·Positive
Roivant Sciences Ltd. (ROIV) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript Roivant Sciences Ltd. (ROIV) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
View source ↗ - Newsseekingalpha.com·26d ago·Positive
Roivant Sciences Ltd. (ROIV) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript Roivant Sciences Ltd. (ROIV) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript
View source ↗ - Newsseekingalpha.com·27d ago·Positive
Roivant Sciences Ltd. (ROIV) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript Roivant Sciences Ltd. (ROIV) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
View source ↗ - Newsseekingalpha.com·27d ago·Positive
Roivant Sciences Ltd. (ROIV) Discusses Top Line Results from PHocus Study of Mosliciguat in PH-ILD Transcript Roivant Sciences Ltd. (ROIV) Discusses Top Line Results from PHocus Study of Mosliciguat in PH-ILD Transcript
View source ↗ - Newsreuters.com·28d ago·Negative
Roivant's experimental lung disease drug meets goals in mid-stage study Roivant said on Tuesday its experimental drug met the main goals of a mid-stage study in patients with high blood pressure associated with a type of lung disease, sending shares up about 20% in premarket trading.
View source ↗ - Newsglobenewswire.com·28d ago·Neutral
…ial Lung Disease (PH-ILD) and Unveils Ongoing Phase 3 PHrontier Study BASEL, Switzerland and LONDON and NEW YORK, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today announced positive results from its Phase 2 PHocus clinical trial evaluating mosliciguat for the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD), a progressive and life-threatening condition with significant unmet medical needs for patients. The results will be presented today at th…
View source ↗ - Newsglobenewswire.com·28d ago·Neutral
…(GLOBE NEWSWIRE) -- Pulmovant, a clinical-stage biotechnology company committed to transforming the lives of patients with pulmonary diseases, and a Roivant (Nasdaq: ROIV) company, today announced positive results from its Phase 2 PHocus clinical trial evaluating mosliciguat for the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD), a progressive and life-threatening condition with significant unmet medical needs for patients. The results will be presented to…
View source ↗ - Newsglobenewswire.com·30d ago·Neutral
…(GLOBE NEWSWIRE) -- Pulmovant, a clinical-stage biotechnology company committed to transforming the lives of patients with pulmonary diseases, and a Roivant (Nasdaq: ROIV) company, today announced that results from the Phase 2 PHocus study of mosliciguat in patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD) will be presented at the European Respiratory Society (ERS) International Congress 2026 at 12:15 CEST (6:15 a.m. ET) on Tuesday, September 8, 2026, by Mar…
View source ↗ - Newsglobenewswire.com·30d ago·Neutral
…S Congress 2026 on Tuesday, September 8, 2026, and Host Investor Call BASEL, Switzerland and LONDON and NEW YORK, Sept. 06, 2026 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) and Pulmovant today announced that results from the Phase 2 PHocus study of mosliciguat in patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD) will be presented at the European Respiratory Society (ERS) International Congress 2026 at 12:15 CEST (6:15 a.m. ET) on Tuesday, September 8, 2026, b…
View source ↗ - Newsseekingalpha.com·38d ago·Positive
Roivant Sciences Ltd. (ROIV) Discusses FDA Approval of LISRAYA as First Oral Targeted Therapy for Dermatomyositis Transcript Roivant Sciences Ltd. (ROIV) Discusses FDA Approval of LISRAYA as First Oral Targeted Therapy for Dermatomyositis Transcript
View source ↗ - Newsmarketbeat.com·38d ago·Negative
Roivant Sciences Wins FDA Approval for LISRAYA in Dermatomyositis, Launches Immediately Roivant Sciences NASDAQ: ROIV said the U.S. Food and Drug Administration has approved LISRAYA, its once-daily oral therapy for adults with dermatomyositis, and that the drug has already entered commercial launch.
View source ↗ - Newsreuters.com·39d ago·Negative
Roivant, Priovant launch newly approved rare disease drug Lisraya at $35,000 a month Roivant and partner Priovant Therapeutics on Friday set a list price of $35,000 for a 30-day supply of their newly approved rare disease drug, Lisraya.
View source ↗ - Newsreuters.com·39d ago·Negative
US FDA approves Roivant-Priovant's skin and muscle disease drug The U.S. Food and Drug Administration said on Thursday it approved a treatment from Roivant and partner Priovant Therapeutics for a rare disease, making it the first oral drug for the condition affecting skin and muscles.
View source ↗ - Newsglobenewswire.com·39d ago·Negative
Roivant Announces FDA Approval of LISRAYA™ (brepocitinib) for Adults with Dermatomyositis; Now Available in the U.S. BASEL, Switzerland and LONDON and NEW YORK, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today announced that the U.S. Food and Drug Administration (FDA) has approved LISRAYA™ (brepocitinib) 30 mg for the treatment of adults with dermatomyositis (DM). LISRAYA is a pill taken once daily.
View source ↗ - Newsglobenewswire.com·39d ago·Negative
Priovant Announces FDA Approval of LISRAYA™ (brepocitinib) for Adults with Dermatomyositis; Now Available in the U.S. DURHAM, N.C., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Priovant Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has approved LISRAYA™ (brepocitinib) 30 mg for the treatment of adults with dermatomyositis (DM). LISRAYA is a pill taken once daily.
View source ↗ - Newsglobenewswire.com·40d ago·Neutral
JAMA Dermatology Publishes Skin-Specific Outcomes from Phase 3 VALOR Trial Of Brepocitinib in Dermatomyositis DURHAM, N.C., Aug. 26, 2026 (GLOBE NEWSWIRE) -- Priovant Therapeutics announced today the publication in JAMA Dermatology of skin-specific outcomes from the Phase 3 VALOR trial evaluating brepocitinib, a first-in-class oral TYK2 and JAK1 inhibitor, in adults with dermatomyositis (DM). Primary efficacy and safety results from the trial were previously published in the New England Journal
View source ↗ - Newsseekingalpha.com·59d ago·Positive
Roivant Sciences: The Balance Sheet Has Become A Strategic Weapon Roivant Sciences is transitioning from an asset-monetization platform to a commercial-stage biopharma, supported by a strong cash position and imminent product launches. ROIV's $4.7 billion pro forma liquidity eliminates near-term dilution risk, enabling commercialization of brepocitinib and continued pipeline investment without adverse equity market reliance. Brepocitinib's FDA Priority Review for dermatomyositis, with potential
View source ↗
Earnings
Mon, Nov 9(in 5 weeks)
Consensus estimate $-0.41 per share
Typical surprise +3.5% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 6$-0.33 vs $-0.30miss
- Wed, May 20$-0.28 vs $-0.29beat
- Fri, Feb 6$-0.24 vs $-0.30beat
- Mon, Nov 10$-0.20 vs $-0.32beat
- Mon, Aug 11$-0.25 vs $-0.25miss
- Thu, May 29$-0.29 vs $-0.26miss
Estimates and results for ROIV via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by ROIV officers and directors.
- Bought
- —
- Sold
- $256.0m
0 trades
39 trades
- Venker Ericsold
- Epperly Melissa B,sold
- Epperly Melissa B,sold
- Fitzgerald Meghansold
- Fitzgerald Meghansold
- Fitzgerald Meghansold
- Venker Ericsold
- Venker Ericsold
61 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Lisa C. McClainhouse · MI09 · disclosed Nov 24, 2025 (25d later)Sell$1,001 - $15,000
- Lisa C. McClainhouse · MI09 · disclosed Nov 24, 2025 (25d later)Buy$1,001 - $15,000
- Lisa C. McClainhouse · MI09 · disclosed Nov 24, 2025 (24d later)Sell$1,001 - $15,000
- Lisa C. McClainhouse · MI09 · disclosed Aug 13, 2025 (57d later)Buy$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.